Transformative Innovation: How India Can Up Its Game, Big Pharma GCCs Add Value
A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.
You may also be interested in...
The arrival of an indigenous CAR-T cell therapy, a shot at GLP-1s and Parkinson’s disease, strides into adjacencies and an “easy revenue stream” formula for products set to lose exclusivity are some of the striking developments seen playing out in India. Industry leaders, including Cipla’s CEO, share their views with Scrip on some of the key trends in the first instalment of this two-part roundup.
In 2024, Sun Pharma’s ADC candidate is expected to be in human trials, while CDMOs like Piramal Pharma Solutions and Aurigene are to operationalize significant new capacities. But can India compensate for a late start on the ADC journey by tapping low development costs and favorable policies, or is it too little with China far ahead in the race?
From Supply Chain To Value Chain: OPPI’s Matai On Moving ‘Up’ Amidst Winds Of Policy Change In India
Incoming director general of the Organisation of Pharmaceutical Producers of India discusses the evolving policy and regulatory landscape in India in areas such as R&D and quality. Stricter adherence to ethical marketing practices could be focus in the coming year, Anil Matai adds.